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The acylphloroglucinol hyperforin (Hyp) from St. John’s wort possesses anti-inflammatory and 
anti-carcinogenic properties which were ascribed among others to the inhibition of 5-lipoxygenase. 
Here, we investigated whether Hyp also interferes with prostanoid generation in biological 
systems, particularly with key enzymes participating in prostaglandin (PG)E2 biosynthesis, i.e., 
cyclooxygenases (COX)-1/2 and microsomal PGE2 synthase (mPGES)-1 which play key roles in 
inflammation and tumorigenesis. Similar to the mPGES-1 inhibitors MK-886 and MD-52, Hyp 
significantly suppressed PGE2 formation in whole blood assays starting at 0.03–1 μM, whereas 
the concomitant generation of COX-derived 12(S)-hydroxy-5-cis-8,10-trans-heptadecatrienoic 
acid, thromboxane B2, and 6-keto PGF1α was not significantly suppressed up to 30 μM. In cell-
free assays, Hyp efficiently blocked the conversion of PGH2 to PGE2 mediated by mPGES-1 
(IC50 = 1 μM), and isolated COX enzymes were not (COX-2) or hardly (COX-1) suppressed. 
Intraperitoneal (i.p.) administration of Hyp (4 mg kg−1) to rats impaired exudate volume and 
leukocyte numbers in carrageenan-induced pleurisy associated with reduced PGE2 levels, and 
Hyp (given i.p.) inhibited carrageenan-induced mouse paw edema formation (ED50 = 1 mg kg
−1) 
being superior over indomethacin (ED50 = 5 mg kg
−1). We conclude that the suppression of 
PGE2 biosynthesis in vitro and in vivo by acting on mPGES-1 critically contributes to the anti-
inflammatory efficiency of Hyp.
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ear edema in mice after topical application (Sosa et al., 2007), 
impaired acute neutrophil recruitment and enhanced resolution 
in a pulmonary bleomycin-induced inflammation model reduc-
ing consequent fibrosis (Dell’Aica et al., 2007), and suppressed 
carrageenan-induced rat pleurisy when given intraperitoneally (i.p.; 
Feisst et al., 2009). Also for humans, topical treatment of atopic 
dermatitis with a Hypericum cream, standardized to 1.5% Hyp, 
revealed significant therapeutic efficacy (Schempp et al., 2003). 
However, despite these well-recognized anti-carcinogenic and anti-
inflammatory effects, the underlying molecular mechanisms and 
targets of Hyp are incompletely understood.
The lipid mediator prostaglandin (PG)E
2
 is a key player in 
inflammation, pain, fever, and cancer but is also known to regulate 
physiological functions in the gastrointestinal tract, in the kidney, 
and in the immune and nervous system (Sugimoto and Narumiya, 
2007). PGE
2
 is formed from arachidonic acid (AA) by cyclooxygen-
ase (COX)-catalyzed synthesis of PGH
2
 and further transformation 
by PGE
2
 synthases (Samuelsson et al., 2007). The microsomal PGE
2
 
synthase (mPGES)-1 is induced by pro-inflammatory stimuli and is 
responsible for excessive PGE
2
 generation connected to pathologies 
(Jakobsson et al., 1999). Co-expression studies indicate a preferred 
functional coupling between mPGES-1 and COX-2 (Murakami 
IntroductIon
Hyperforin (Hyp), a polyprenylated acylphloroglucinol (Figure 
1A), is assumed to be one of the main active components of St. 
John’s wort, which is frequently used for the treatment of mild to 
moderate depressions (Muller, 2003). Besides its antidepressant 
activity, Hyp also exerts potent anti-inflammatory and anti-tu-
moral effects (Medina et al., 2006). Hyp was shown to reduce tumor 
cell growth (Schempp et al., 2002; Hostanska et al., 2003), cancer 
invasion, metastasis (Dona et al., 2004), angiogenesis (Martinez-
Poveda et al., 2005), and lymphatic capillary growth (Rothley et al., 
2009). On the cellular level, Hyp decreases proliferation rates and 
causes apoptosis of leukemic cells (Schempp et al., 2002; Quiney 
et al., 2006) and various cancer cell lines (Schempp et al., 2002; 
Hostanska et al., 2003; Dona et al., 2004), and also inhibits prolifera-
tion of non-transformed T lymphocytes (Schempp et al., 2000). In 
regard of its anti-inflammatory potential, Hyp blocks several pro-
inflammatory functions of leukocytes in vitro such as chemotaxis 
and chemoinvasion (Dell’Aica et al., 2007; Lorusso et al., 2009), 
suppresses receptor-mediated Ca2+-mobilization and eicosanoid 
release in leukocytes (Albert et al., 2002; Feisst and Werz, 2004), 
and down-regulates effector functions of activated T lymphocytes 
(Cabrelle et al., 2008). In vivo, Hyp reduced croton-oil-induced 
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flasks. Cell viability was assessed using the colorimetric thiazolyl 
blue tetrazolium bromide dye reduction assay (MTT assay). A549 
cells (4 × 104 cells per 100 μl medium) were plated into a 96-well 
microplate and incubated at 37°C and 5% CO
2
 for 16 h. Then, Hyp 
(30 μM) was added, and the samples were incubated for another 
5 h. Thiazolyl blue tetrazolium bromide (20 μl, 5 mg ml−1) was 
added and the incubations were continued for 4 h. The formazan 
product was solubilized with sodium dodecylsulfate (SDS, 10%, 
m v−1 in 20 mM HCl), and the absorbance was measured at 595 nm 
relative to the absorbance of vehicle (DMSO)-treated control cells 
using a multiwell scanning spectrophotometer (Victor3 plate reader, 
PerkinElmer, Rodgau-Juegesheim, Germany).
AnImAls
Male adult CD1 mice (25–35 g, Harlan, Milan, Italy) and Wistar Han 
rats (190–200 g, Harlan, Milan, Italy) were housed in a controlled 
environment and provided with standard rodent chow and water. 
Animal care complied with Italian regulations on protection of ani-
mals used for experimental and other scientific purpose (Ministerial 
Decree 116192) as well as with the European Economic Community 
regulations (Official Journal of E.C. L 358/1 12/18/1986).
determInAtIon of PGe2, 6-keto PGf1α, And tXB2 formAtIon In 
lPs-stImulAted humAn whole Blood
Peripheral blood from healthy adult volunteers, who had not 
received any medication for at least 2 weeks under informed con-
sent, was obtained by venepuncture and collected in syringes con-
taining heparin (20 U ml−1). For determination of PGE
2
 and 6-keto 
PGF
1α, aliquots of whole blood (0.8 ml) were mixed with the TX 
synthase inhibitor CV4151 (1 μM) and with aspirin (50 μM) to 
establish experimental conditions where prostanoids are essentially 
produced via the COX-2 pathway (Koeberle et al., 2008). For the 
determination of TXB
2
, whole blood aliquots were not pretreated 
with aspirin and CV4151. A total volume of 1 ml was adjusted with 
sample buffer (10 mM potassium phosphate buffer pH 7.4, 3 mM 
KCl, 140 mM NaCl, and 6 mM d-glucose). After pre-incubation 
with the indicated compounds for 5 min at room temperature, 
the samples were stimulated with LPS (10 μg ml−1) for 5 h at 37°C. 
Prostanoid formation was stopped on ice, the samples were cen-
trifuged (2300 × g, 10 min, 4°C), and 6-keto PGF
1α and TXB2 were 
quantified in the supernatant using a 6-keto PGF
1α or TXB2 high 
sensitivity EIA kit (Assay Designs, Ann Arbor, MI, USA) according 
to the manufacturer’s protocol. PGE
2
 was determined after solid 
phase extraction and HPLC separation using a PGE
2
 high sensi-
tivity EIA kit (Assay Designs, Ann Arbor, MI, USA) as described 
(Koeberle et al., 2008). The mPGES-1 inhibitors MK-886 (30 μM) 
and MD52 (6 μM), the COX-1/2 inhibitor indomethacin (50 μM) 
and the COX-2-selective inhibitor celecoxib (20 μM) were used as 
control. Care should be taken when interpreting the controls in 
respect to COX-1/2 isoenzyme specificity which was not further 
evaluated for our experimental settings.
determInAtIon of ProstAnoId formAtIon from eXoGenous AA 
In humAn whole Blood
Heparinized human blood, supplemented with penicillin 
(100 U ml−1) and streptomycin (100 μg ml−1), was treated with 
10 μg ml−1 LPS for 16 h at 37°C and 5% CO
2
. Then, CV4151 (1 μM) 
and Kudo, 2006), and data from mPGES-1 knockout mice and 
animal studies with selective mPGES-1 inhibitors suggest key roles 
of mPGES-1 in inflammation, pain, fever, atherosclerosis, and tum-
origenesis (Samuelsson et al., 2007; Friesen and Mancini, 2008; 
Koeberle and Werz, 2009).
We have previously shown that Hyp inhibits leukotriene bio-
synthesis in neutrophils (IC
50
 = 1–2 μM) by interference with the 
C2-like domain of 5-lipoxygenase (5-LO), and we observed an 
inhibitory effect of Hyp also on COX-1 activity in human plate-
lets (IC
50
 = 3 μM; Albert et al., 2002; Feisst et al., 2009). However, 
COX-2 activity (measured as 6-keto PGF
1α synthesis) in monocytic 
Mono Mac 6 cells was not affected up to 30 μM Hyp. This is sur-
prising because Hammer et al. (2007) recently demonstrated that 
Hyp inhibits the release of PGE
2
 from lipopolysaccharide (LPS)-
stimulated murine (RAW264.7) macrophages, a process coupled to 
COX-2 as well. Here, we identified mPGES-1 as functional target 
of Hyp and suggest that interference with mPGES-1 suppresses 
PGE
2
 biosynthesis in vivo and contributes to the anti-inflammatory 
effectiveness in related animal models.
mAterIAls And methods
reAGents
Hyperforin dicyclohexylammonium salt and the Hypericum perfo-
ratum extract were obtained from Dr. Willmar Schwabe GmbH & Co 
(Karlsruhe, Germany), respectively. The compounds and the extract 
were dissolved in dimethyl sulfoxide (DMSO) and kept in the dark 
at −20°C, and freezing–thawing cycles were kept to a minimum. 
For animal studies, Hyp was dissolved in DMSO and diluted with 
saline achieving a final DMSO concentration of 2–4%. The throm-
boxane (TX) synthase inhibitor CV4151 (Kato et al., 1985) and the 
mPGES-1 inhibitor 2-(2-chlorophenyl)-1H-phenanthro[9,10-d]-
imidazole (MD-52; Côté et al., 2007) were kindly provided by Dr. 
S. Laufer (University of Tübingen, Germany) and Dr. M. Schubert-
Zsilavecz (University of Frankfurt, Germany), respectively. The 
antibody against human mPGES-1 was from Cayman Chemical 
(Ann Arbor, MI, USA), antibodies against COX-2 and β-actin were 
obtained from Sigma-Aldrich (Deisenhofen, Germany) and the 
antibody against cleaved poly(ADP-ribose)polymerase (PARP) was 
purchased from Cell Signaling Technology (Danvers, MA, USA). 
Materials used: DMEM high glucose (4.5 g l−1) medium, penicil-
lin, streptomycin, trypsin–EDTA solution, sodium pyruvate, PAA 
(Coelbe, Germany); PGH
2
, Larodan (Malmö, Sweden); 11β-PGE
2
, 
MK-886, PGB
1
, human recombinant COX-2, ovine isolated COX-1, 
Cayman Chemical (Ann Arbor, MI, USA). λ-Carrageenan type IV 
isolated from Gigartina aciculaire and G. pistillata was purchased 
from Sigma-Aldrich (Milan, Italy). 3H-PGE
2
 was from PerkinElmer 
Life Sciences (Milan, Italy) and PGE
2
 antibody from Sigma-Aldrich 
(Milan, Italy). All other chemicals were obtained from Sigma-
Aldrich (Deisenhofen, Germany) unless stated otherwise.
cells And cell vIABIlIty AssAy
Human lung carcinoma A549 cells were cultured in DMEM high 
glucose (4.5 g l−1) medium supplemented with heat-inactivated 
fetal calf serum (FCS, 10%, v v−1), penicillin (100 U ml−1), and 
streptomycin (100 μg ml−1) at 37°C in a 5% CO
2
 incubator. After 
3 days, confluent cells were detached using 1 × trypsin–EDTA solu-
tion and reseeded at 2 × 106 cells in 20 ml medium in 175 cm2 
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sds-PAGe And western Blot
Cells (4 × 106 cells) were resuspended in 50 μl PBS buffer pH 7.2, 
mixed with the same volume of 2 × SDS/PAGE sample loading buffer 
(20 mM Tris–HCl, pH 8, 2 mM EDTA, 5% (m v−1) SDS, and 10% 
(v v−1) β-mercaptoethanol), and boiled for 5 min at 95°C. Aliquots 
(20 μl) corresponding to equivalents of 0.8 × 106 cells were mixed 
with 4 μl glycerol/0.1% bromophenol blue (1:1, v v−1), and proteins 
were separated by SDS-PAGE. After electroblotting to nitrocellulose 
membrane (GE Healthcare, Munich, Germany) and blocking with 
5% BSA for 1 h at room temperature, membranes were washed and 
incubated with primary antibodies overnight at 4°C. The mem-
branes were washed and incubated with a 1:1000 dilution of alka-
line phosphatase-conjugated immunoglobulin G for 3 h at room 
temperature. After washing, proteins were visualized with nitro blue 
tetrazolium and 5-bromo-4-chloro-3-indolylphosphate.
cArrAGeenAn-Induced PAw edemA In mIce
Mice were divided into groups (n = 10 for each group) and lightly 
anesthetized with enflurane 4% mixed with O
2
, 0.5 l min−1, N
2
O 
0.5 l min−1. Each group of animals received subplantar adminis-
tration of saline (0.05 ml) or of λ-carrageenan type IV 1% (w v−1, 
0.05 ml) in saline. The paw was marked in order to immerge it 
always at the same extent in the measurement chamber. The volume 
was measured by using a hydroplethismometer, specially modified 
for small volumes (Ugo Basile, Milan, Italy), immediately before 
subplantar injection and 2, 4, and 6 h thereafter (Posadas et al., 
2004). The assessment of paw volume was performed always in 
double blind and by the same operator. The increase in paw volume 
was calculated by subtracting the initial paw volume (basal) to the 
paw volume measured at each time point.
cArrAGeenAn-Induced PleurIsy In rAts
Rats were anesthetized with enflurane 4% mixed with O
2
, 0.5 l min−1, 
N
2
O 0.5 l min−1 and submitted to a skin incision at the level of the 
left sixth intercostal space. The underlying muscle was dissected, 
and saline (0.2 ml) or λ-carrageenan type IV 1% (w v−1, 0.2 ml) 
was injected into the pleural cavity. The skin incision was closed 
with a suture, and the animals were allowed to recover. At 4 h after 
the injection of carrageenan, the animals were killed by inhalation 
of CO
2
. The chest was carefully opened, and the pleural cavity was 
rinsed with 2 ml saline solution containing heparin (5 U ml−1). The 
exudate and washing solution were removed by aspiration, and the 
total volume was measured. Any exudate that was contaminated 
with blood was discarded. The amount of exudate was calculated by 
subtracting the volume injected (2 ml) from the total volume recov-
ered. Leukocytes in the exudate were resuspended in phosphate 
buffered saline (PBS) and counted with an optical light microscope 
in a Burker’s chamber after vital trypan blue staining.
The amount of PGE
2
 in the supernatant of centrifuged exudate 
(800 × g for 10 min) was assayed by radioimmunoassay according 
to manufacturer’s protocol. The results are expressed as nanograms 
per rat and represent the mean ± SE of 10 rats.
stAtIstIcs
Data are expressed as mean ± SE. IC
50
 values were calculated by 
nonlinear regression using SigmaPlot 9.0 (Systat Software Inc., San 
Jose, USA) one site binding competition. The program Graphpad 
was added, and after pre-incubation with the indicated compounds 
for 10 min at 37°C, prostanoid formation was initiated by addition 
of 20 μM AA. In contrast to the LPS-stimulated whole blood assay 
described above, whole blood aliquots were not pretreated with 
aspirin (inhibition of COX-1 product formation) because both 
COX-1 and -2 are described to contribute to mPGES-1-dependent 
PGE
2
 synthesis at high AA concentrations (Murakami et al., 2000). 
PGE
2
 or 6-keto PGF
1α formation within 10 min was determined as 
described for LPS-stimulated whole blood. Calculated prostanoid 
levels were corrected by the amount of PGE
2
 formed during pre-
stimulation with LPS.
For determination of the COX product 12(S)-hydroxy-5-cis-
 8,10-trans-heptadecatrienoic acid (12-HHT), freshly drawn human 
blood (2 ml) was pre-incubated with the indicated compounds 
at 37°C for 10 min, and formation of 12-HHT was initiated by 
addition of 30 μM Ca2+-ionophore A23187 plus 100 μM AA. After 
10 min at 37°C, formed 12-HHT was extracted from plasma and 
analyzed by HPLC using PGB
1
 as internal standard as described 
(Capdevila et al., 1995).
ActIvIty AssAys of IsolAted coX-1 And coX-2
Inhibition of the activities of isolated ovine COX-1 and human 
COX-2 was performed as described (Koeberle et al., 2008). 
Briefly, purified COX-1 (ovine, 50 units) or COX-2 (human 
recombinant, 20 units) were diluted in 1 ml reaction mixture 
containing 100 mM Tris buffer pH 8, 5 mM glutathione, 5 μM 
hemoglobin, and 100 μM EDTA at 4°C and pre-incubated with 
the test compounds for 5 min. Samples were pre-warmed for 
60 s at 37°C, and AA (5 μM for COX-1, 2 μM for COX-2) was 
added to start the reaction. After 5 min at 37°C, the COX product 
12-HHT was extracted and then analyzed by HPLC as described 
(Albert et al., 2002).
PrePArAtIon of crude mPGes-1 In mIcrosomes of A549 cells And 
determInAtIon of PGe2 synthAse ActIvIty
Preparation of A549 cells and determination of mPGES-1 activity 
was performed as described previously (Koeberle et al., 2008). 
In brief, cells were incubated for 16 h at 37°C and 5% CO
2
, the 
medium was replaced, 1 ng ml−1 interleukin (IL)-1β was added, 
and cells were incubated for another 48 h. After sonication, 
the homogenate was subjected to differential centrifugation at 
10,000 × g for 10 min and 174,000 × g for 1 h at 4°C. The pellet 
(microsomal fraction) was resuspended in 1 ml homogeniza-
tion buffer (0.1 M potassium phosphate buffer pH 7.4, 1 mM 
phenylmethanesulfonyl fluoride, 60 μg ml−1 soybean trypsin 
inhibitor, 1 μg ml−1 leupeptin, 2.5 mM glutathione, and 250 mM 
sucrose), and the total protein concentration was determined. 
Microsomal membranes were diluted in potassium phosphate 
buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione to a final 
protein concentration of approx. 70 μg ml−1. Test compounds or 
vehicle were added, and after 15 min at 4°C, the reaction (100 μl 
total volume) was initiated by addition of PGH
2
 (20 μM, final 
concentration). After 1 min at 4°C, the reaction was terminated 
using stop solution (100 μl; 40 mM FeCl
2
, 80 mM citric acid, and 
10 μM of 11β-PGE
2
 as internal standard). PGE
2
 was separated 
by solid phase extraction and analyzed by HPLC as described 
(Koeberle et al., 2008).
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30 μM) can be excluded as determined by an A549 cell viability assay 
measuring mitochondrial dehydrogenase activity (see Materials 
and Methods, data not shown). The selective mPGES-1 inhibi-
tor MD-52 (Côté et al., 2007) and the combined 5-LO-activating 
protein (FLAP), COX-1 and mPGES-1 inhibitor MK-886 (Claveau 
et al., 2003; Koeberle et al., 2009b) were used as reference (see also 
Koeberle et al., 2008). PGE
2
 levels were neither completely sup-
pressed by the mPGES-1 inhibitors nor by Hyp, even not at high 
Hyp concentrations (30 μM) or prolonged incubation times (24 h, 
data not shown). In contrast, the COX-1/2 inhibitor indomethacin 
(50 μM) and the COX-2 selective celecoxib (20 μM) effectively 
reduced PGE
2
 (Figure 1B) almost to the level of the unstimulated 
control (PGE
2
: 14.2 ± 8.4%). Celecoxib and/or indomethacin also 
inhibited the formation of 6-keto PGF
1α (the stable metabolite of 
PGI
2
, Figure 1C) and TXB
2
 (Figure 1D) as expected, whereas Hyp 
(up to 30 μM), MD-52, and MK-886 failed to suppress the forma-
tion of 6-keto PGF
1α (Figure 1C) and TXB2 (Figure 1D) under the 
Instat (Graphpad Software Inc., San Diego, CA, USA) was used 
for statistical comparisons. Statistical evaluation of the data was 
performed by one-way or two-way ANOVAs for independent 
or correlated samples followed by Tukey HSD post hoc tests. A P 
value < 0.05 (*) was considered significant.
results
effects of hyPerforIn on ProstAnoId formAtIon In humAn 
whole Blood
Hyperforin was recently shown to inhibit the production of PGE
2
 
in LPS-stimulated RAW264.7 mouse macrophages (Hammer 
et al., 2007). Here, we investigated the effects of Hyp on prosta-
noid formation in human whole blood pre-incubated with Hyp 
for 5 min and stimulated with LPS for 5 h. Hyp concentration-
dependently suppressed PGE
2
 formation with an apparent IC
50
 of 
approx. 3 μM reaching significant inhibition at 1 μM (25 ± 3% 
inhibition; Figure 1B). Acute (5 h) cytotoxic effects of Hyp (up to 
FigurE 1 | Effects of hyperforin on prostanoid formation in LPS-stimulated 
human whole blood. (A) Chemical structure of Hyp. (B,C) Heparinized human 
whole blood, treated with 1 μM TX synthase inhibitor CV4151 and 50 μM aspirin, 
was pre-incubated with the indicated agents or vehicle (DMSO) for 5 min at 
room temperature, and then, prostanoid formation was induced by addition of 
10 μg ml−1 LPS. After 5 h at 37°C, PGE2 (B) was extracted from plasma by RP-18 
solid phase extraction, separated by RP-HPLC, and quantified by ELISA as 
described. 6-Keto PGF1α (C) and TXB2 (D) were directly determined in the 
plasma by ELISA. The 100% values correspond to prostanoid levels in the range 
of 14–27 ng ml−1 PGE2, 3–5 ng ml
−1 6-keto PGF1α, and 47–64 ng ml
−1 TXB2 in the 
individual experiments, respectively. MK-886 (30 μM), MD-52 (6 μM), 
indomethacin (Indo, 50 μM), and celecoxib (Cele, 20 μM) were used as controls. 
Data are given as mean ± SE, n = 3–4, *p < 0.05, ***p < 0.001 vs. vehicle (0.1% 
DMSO) control, ANOVA + Tukey HSD post hoc tests.
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same experimental conditions. Together, unlike COX inhibitors 
but as like mPGES-1 inhibitors, Hyp selectively suppresses PGE
2
 
formation but not the synthesis of other prostanoids such as 6-keto 
PGF
1α or TXB2.
Hyperforin may suppress PGE
2
 formation by interference with 
LPS-signaling, mPGES-1 expression or liberation of AA as substrate 
for COX enzymes. Thus, heparinized human whole blood was first 
incubated with LPS for 16 h to induce the expression of COX-2 
and mPGES-1 (in contrast to constitutively expressed COX-1 and 
cPGES). Then, the blood was pre-incubated with Hyp for 10 min, 
and prostanoid formation was initiated by addition of 20 μM AA. 
After 10 min at 37°C, generation of PGE
2
 and 6-keto PGF
1α was 
determined in plasma as described above. PGE
2
 formation was 
potently inhibited by Hyp in a concentration-dependent manner 
with an IC
50
 of 0.25 μM reaching significance at 30 nM (Figure 2A), 
whereas formation of 6-keto PGF
1α was not significantly affected 
up to 30 μM (Figure 2B), again indicating selective suppression of 
PGE
2
 biosynthesis by Hyp. Note that Hyp (3–30 μM) was more effi-
cient in suppressing PGE
2
 synthesis after long-term pre-stimulation 
with LPS (induction of COX-2 and mPGES-1, Figure 2A) than 
during short term stimulation (Figure 1B) supporting that Hyp 
interferes with the inducible COX-2/mPGES-1 pathway.
In order to assess the effects of Hyp on the activity of COX-1 
in whole blood (constitutively expressed in platelets), freshly with-
drawn human blood (no incubation with LPS) was pre-incubated 
with Hyp for 10 min at 37°C, treated with Ca2+-ionophore and 
100 μM AA for another 10 min, and the formation of 12-HHT 
(mainly derived from platelet COX-1) was determined. Hyp (up 
to 30 μM) failed to suppress 12-HHT formation under these assay 
conditions, whereas indomethacin and aspirin almost completely 
blocked it (Figure 2C). In conclusion, the data suggest that Hyp 
potently and selectively blocks PGE
2
 formation in whole blood 
without markedly affecting COX-1/2.
effects of hyPerforIn on the ActIvIty of IsolAted coX-1 
And coX-2
We determined the direct interference of Hyp with the catalytic 
activity of isolated COX enzymes. Purified ovine COX-1 and 
human recombinant COX-2 were pre-incubated with Hyp for 
5 min prior to addition of AA (5 μM for COX-1, 2 μM for COX-2). 
Formation of 12-HHT, the major COX-1/2-derived product under 
these experimental conditions (Capdevila et al., 1995), was analyzed 
by RP-HPLC. Hyp concentration-dependently reduced 12-HHT 
formation by COX-1 with an IC
50
 = 12 μM (Figure 3A), whereas 
COX-2 was not significantly inhibited up to 30 μM (Figure 3B). 
The reference compounds indomethacin (10 μM) and celecoxib 
(5 μM) potently inhibited 12-HHT formation, as expected.
InhIBItIon of mPGes-1 ActIvIty By hyPerforIn
Because Hyp potently inhibited PGE
2
 formation in whole blood from 
AA but failed to block COX-2, inhibition of PGE
2
 synthesis down-
stream of COX-2 (i.e., interference with PGE
2
 synthases) appeared 
reasonable. mPGES-1 is the major PGE
2
 synthase under pathological 
conditions related to inflammation and cancer (Samuelsson et al., 
2007), and its expression is strongly increased in blood upon LPS 
treatment, primarily contributing to PGE
2
 formation in blood (Mosca 
et al., 2007). To assess the effects of Hyp on mPGES-1  activity, micro-
FigurE 2 | Effects of hyperforin on arachidonic acid-induced prostanoid 
formation in human whole blood. (A,B) Heparinized human whole blood 
was treated with 10 μg ml−1 LPS for 16 h at 37°C and 5% CO2, supplemented 
with TX synthase inhibitor CV4151 (1 μM), and pre-incubated with Hyp or 
vehicle (DMSO) for 10 min at 37°C. (A) Then, PGE2 formation was initiated 
with 20 μM AA, and PGE2 formed within 10 min was separated by RP-HPLC 
and quantified by ELISA. The 100% value corresponds to PGE2 levels in the 
range of 18–31 ng ml−1 in the individual experiments, respectively. (B) 6-keto 
PGF1α was directly determined in the plasma by ELISA. The 100% value 
corresponds to 6-keto PGF1α levels in the range of 4–7 ng ml
−1. Indomethacin 
(Indo, 50 μM) and celecoxib (Cele, 20 μM) were used as controls. (C) 12-HHT 
formation in whole blood. Heparinized whole blood was pre-incubated with 
Hyp or vehicle (DMSO) for 10 min, and AA (100 μM) and Ca2+-ionophore 
(30 μM) were added to induce 12-HHT product formation. After 10 min at 
37°C, 12-HHT was extracted form the plasma by RP-18 solid phase extraction 
and analyzed by RP-HPLC as described. The 100% value corresponds to 
1.5–2.4 μg ml−1 12-HHT. Indomethacin (Indo, 20 μM) and aspirin (ASA, 30 μM) 
were used as controls. Data are given as mean ± SE, n = 3–5, *p < 0.05, 
**p < 0.01 or ***p < 0.001 vs. vehicle (0.1% DMSO) control, ANOVA + Tukey 
HSD post hoc tests.
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cell line to study mPGES-1 functions), and also β-actin levels were 
slightly reduced at 10 μM (Figure 5). Since previous studies showed 
that Hyp causes apoptosis of various cancer cell lines (Schempp 
et al., 2002; Hostanska et al., 2003; Dona et al., 2004), we reasoned 
that reduced expression of COX-2 and mPGES-1 in A549 cells 
by Hyp may be related to induction of apoptotic cell death. In 
fact, the decrease of COX-2 and mPGES-1 protein correlated with 
the induction of apoptosis as determined by the cleavage of PARP 
(Figure 5), and the cell viability was strongly reduced after 24 h 
(EC
50
 ≈ 3 μM, not shown).
hyPerforIn suPPresses cArrAGeenAn-Induced mouse PAw 
edemA
The anti-inflammatory properties of Hyp were investigated in 
carrageenan-induced mouse paw edema in which PGE
2
 (and 
also other mediators) critically contributes to the inflammatory 
response (Guay et al., 2004). Hyp (0.25, 1, 4 mg kg−1) was admin-
istered i.p. 30 min prior to injection of carrageenan into the mouse 
paw. The increase in paw volume was time-dependently assessed 
and reached a maximum at 4-h post-carrageenan treatment (Figure 
6A). In fact, in mice treated with 0.25, 1, and 4 mg kg−1 of Hyp, the 
peak of the response to carrageenan at 4 h was reduced by 35, 63, 
and 78%, respectively, whereas indomethacin (5 mg kg−1), used as 
reference, caused 57% inhibition. Moreover, comparison of the 
areas under the curves of each group, between 2 and 6 h after car-
rageenan injection, yielded similar degrees of inhibition confirming 
a more potent effect of Hyp (ED
50
 = 1 mg kg−1) over indomethacin 
(ED
50
 = 5 mg kg−1; Figure 6B).
hyPerforIn suPPresses cArrAGeenAn-Induced PleurIsy In rAts
Hyperforin has previously been shown to suppress carrageenan-
induced pleurisy in rats by decreasing pleural LTB
4
 levels (Feisst 
et al., 2009). Here, we further assessed the formation of PGE
2
 during 
pleurisy in order to get some information about its ability to inhibit 
PGE
2
 synthesis in vivo. Injection of carrageenan into the pleural 
cavity of rats (DMSO 4% group) elicited an acute inflammatory 
response characterized by the accumulation of fluid that contained 
large numbers of inflammatory cells (Table 1). As observed in car-
rageenan-induced paw edema, Hyp (4 mg kg−1 i.p., 30 min before 
carrageenan) significantly inhibited the inflammatory response 
4 h after carrageenan injection as demonstrated by the significant 
attenuation of exudate formation (64%) and cell infiltration (50%). 
Indomethacin (5 mg kg−1) also reduced exudate formation and cell 
infiltration (75 and 65%, respectively), and its anti-inflammatory 
action is not significantly different from Hyp (Table 1). In com-
parison with the corresponding exudates from DMSO-treated rats, 
exudates of Hyp-treated animals exhibited significantly decreased 
PGE
2
 levels, and indomethacin almost completely suppressed PGE
2
 
formation as expected (Table 1).
dIscussIon
Systematic investigations of Hyp’s pharmacological action within 
the PGE
2
 biosynthetic pathway revealed mPGES-1 as a putative 
molecular target of Hyp. Thus, Hyp potently and concentration-
dependently inhibited the enzymatic conversion of PGH
2
 to PGE
2
 
catalyzed by mPGES-1 in a defined cell-free assay, diminished the 
formation of PGE
2
 in human whole blood without affecting the 
somal preparations of IL-1β-stimulated A549 cells, a rich source 
of mPGES-1 (Jakobsson et al., 1999), were used. Microsomes were 
pre-incubated with Hyp for 15 min, and then, PGE
2
 formation was 
initiated by addition of 20 μM PGH
2
 as substrate for mPGES-1. 
MK-886, used as reference compound, concentration-dependently 
inhibited PGE
2
 formation with an IC
50
 of 2.1 μM (data not shown), 
which is in agreement with the literature (Koeberle et al., 2008). As 
shown in Figure 4A, Hyp concentration-dependently suppressed 
PGE
2
 formation with an IC
50
 of 1 μM, and at 10 μM, 85 ± 2% inhibi-
tion was evident. Decreasing the PGH
2
 concentration to 1 μM did not 
significantly alter the potency of Hyp (data not shown). Interestingly, 
octahydro-hyperforin was equally effective, whereas the acylphloro-
glucinol core or the closely related polyprenylated acylphloroglucinol 
humulone (Figure 4B) failed to significantly inhibit PGE
2
 formation 
up to 10 μM (Figure 4A). These data suggest that defined structural 
arrangements are required for Hyp’s inhibitory effect on mPGES-1. 
Finally, also an ethanolic extract (60% ethanol, v v−1) of St. John’s 
wort proved to be efficient in suppressing PGE
2
 formation with an 
ED
50
 = 4 μg ml−1 (Figure 4C).
To investigate whether Hyp inhibits PGE
2
 synthesis in a reversible 
manner, microsomal preparations of A549 cells were pre-incubated 
with Hyp and subjected to wash-out experiments. Hyp at 0.3 μM 
failed to efficiently block PGE
2
 synthesis, whereas PGE
2
 formation 
was efficiently blocked at 3 μM (Figure 4D). mPGES-1 activity was 
restored by 10-fold dilution of the sample containing 3 μM Hyp 
(Figure 4D) implying a reversible mode of inhibition.
effects of hyPerforIn on the eXPressIon of coX-2 And mPGes-1 
And InductIon of APoPtotIc cell deAth
We investigated whether Hyp might suppress PGE
2
 formation by 
interfering with COX-2 or mPGES-1 expression during prolonged 
incubation times (24 h). In fact, Hyp concentration-dependently 
inhibited the induction of COX-2 and mPGES-1 with an EC
50
 of 
1–3 μM in IL-1β-stimulated A549 cells (a model lung carcinoma 
FigurE 3 | Effects of hyperforin on the activity of isolated COX-1 and -2. 
Purified ovine COX-1 [(A) 50 units] or human recombinant COX-2 [(B) 20 units] 
were added to a COX reaction mix containing 5 mM glutathione. The COX 
enzymes were pre-incubated with the test compounds for 5 min, and then, 
the reaction was started with 5 μM (COX-1) or 2 μM (COX-2) AA. After 5 min 
at 37°C, the formation of 12-HHT was determined by RP-HPLC as described. 
The 100% values in individual experiments are in the range of 110–140 ng ml−1 
and 90–120 ng ml−1 12-HHT for COX-1 and COX-2 assays, respectively. 
Indomethacin (Indo, 10 μM) and celecoxib (Cele, 5 μM) were used as controls. 
Data are given as mean ± SE, n = 3, *p < 0.05, ***p < 0.001 vs. vehicle (0.1% 
DMSO) control, ANOVA + Tukey HSD post hoc tests.
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5-LO forms the basis of the anti-inflammatory effectiveness of Hyp 
and St. John’s wort observed in vitro and in vivo (Schempp et al., 
2003; Medina et al., 2006; Hammer et al., 2007; Sosa et al., 2007).
St. John’s wort is frequently used for the treatment of mild and 
moderate depressions but also to intervene with inflammatory 
disorders, peptic ulcers, and skin wounds (Medina et al., 2006). 
Although the anti-depressive, anti-inflammatory, and anti-carci-
nogenic effects of St. John’s wort extracts could be ascribed to Hyp 
(Muller, 2003; Medina et al., 2006), the underlying molecular mech-
anisms and molecular targets of Hyp are still elusive. Postulated 
anti-inflammatory mechanisms include down-regulation of the 
expression of the chemokine receptor CXCR3 on activated T cells 
(Cabrelle et al., 2008), down-modulation of matrix metallopro-
teinase 9, seemingly due to inhibition of leukocyte elastase, and 
reduced expression of the adhesion molecule CD11b in neutrophils 
synthesis of other COX-derived prostanoids (i.e., 6-keto PGF
1α, 
TXB
2
, and 12-HHT), and reduced PGE
2
 levels in the pleurisy model 
in vivo. COX-2, phospholipases, or LPS-signaling components as 
possible point of attack were excluded based on cell-free and cellular 
assays of COX-2 activity and by experiments applying exogenous 
AA as substrate for COX enzymes. Discrepancies were observed in 
the potency of Hyp to inhibit COX-1 activity between whole blood 
(Figure 2C) and cell-free assays (Figure 3A) or platelet COX-1 
activity assays (Feisst and Werz, 2004) which apparently do not 
solely depend on plasma protein binding and are not readily under-
stood. The pharmacological relevance of the inhibition of mPGES-1 
and, as previously reported, 5-LO (Feisst and Werz, 2004) is sup-
ported by the beneficial effect of Hyp during eicosanoid (mainly 
PGE
2
)-driven acute inflammation in mouse paw edema and rat 
pleurisy. We suggest that the dual interference with mPGES-1 and 
FigurE 4 | Effects of hyperforin on the activity of mPgES-1. (A) 
Concentration–response curves for Hyp, octahydro-hyperforin, the 
acylphloroglucinol core, and humulone. (B) Chemical structures of octahydro-
hyperforin, the acylphloroglucinol core, and humulone. (C) Concentration–
response curves for a St. John’s wort extract. (A,C) For studies of mPGES-1 
inhibition, microsomal preparations of IL-1β-stimulated A549 cells were 
pre-incubated with vehicle (DMSO) or the test compounds at the indicated 
concentrations for 15 min at 4°C, and the reaction was started with 20 μM 
PGH2. After 1 min at 4°C, the reaction was terminated using a stop solution 
containing FeCl2 and 11β-PGE2 (1 nmol) as internal standard. The 100% values in 
the individual experiments are in the range of 3–4 μg ml−1 PGE2. Data are given 
as mean ± SE, n = 3–4. (D) Reversibility of mPGES-1 inhibition by Hyp. 
Microsomal preparations of IL-1β-stimulated A549 cells were pre-incubated with 
3 μM inhibitor for 15 min at 4°C. An aliquot was diluted 10-fold to obtain an 
inhibitor concentration of 0.3 μM. For comparison, microsomal preparations 
were pre-incubated for 15 min with 0.3 μM Hyp or with vehicle (DMSO), and 
then, 20 μM PGH2 was added (no dilution). Then, all samples were incubated for 
1 min on ice, and PGE2 formation was analyzed as described by RP-HPLC. Data 
are given as mean ± SE, n = 3–4, **p < 0.01 vs. vehicle (0.1% DMSO) control, 
ANOVA + Tukey HSD post hoc tests.
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characterized based on cell-free assays and assays based on isolated 
cells, and thus, the pharmacological relevance of these postulates 
is unclear. These assays lack the influence of a physiologically rel-
evant environment as compared to studies using whole blood or 
tissues, and important factors (plasma protein binding, cell–cell 
interactions, etc.) that may potentially modulate the efficacy are 
therefore neglected. Moreover, the effective concentrations of Hyp 
for intervention with certain targets or mechanisms are often sub-
stantially higher (>1 μM) than Hyp levels reached in vivo after oral 
administration of St. John’s wort preparations. Thus, daily oral 
intake of 3 × 300 mg hypericum extract by human volunteers led 
to Hyp steady-state concentrations of 0.28 μM (Biber et al., 1998). 
In light of these facts, suppression of PGE
2
 formation by Hyp was 
evident in human whole blood with significant suppressive effects 
at 0.03–1 μM, congruent with the ability of Hyp to directly interfere 
with mPGES-1 activity in the cell-free assay (IC
50
 = 1 μM).
Hyperforin almost completely blocked mPGES-1 activity in the 
cell-free assay, but PGE
2
 formation in LPS-stimulated whole blood 
was only partially inhibited (residual PGE
2
 formation approx. 50% 
of vehicle control) as observed for mPGES-1 inhibitors such as 
MK-886 (this study and Koeberle et al., 2008), MD-52 (this study 
and Koeberle et al., 2009a), and others (Koeberle and Werz, 2009). 
In contrast, COX inhibitors (i.e., indomethacin or celecoxib) were 
markedly more effective to suppress PGE
2
 formation in whole 
blood. Possibly, constitutively expressed homeostatic PGE synthases 
contribute to PGE
2
 synthesis under these conditions and are not 
inhibited by Hyp. In fact, when whole blood was first pre-incubated 
with LPS to induce COX-2- and mPGES-1-expression (in con-
trast to the expression of constitutively expressed COX-1 or PGE
2
 
synthases like cPGES and mPGES-2, Murakami and Kudo, 2006), 
Hyp showed an increased efficiency to reduce PGE
2
 formation. 
The contribution of PGE
2
 synthases others than mPGES-1 may 
also explain the incomplete suppression of PGE
2
 formation in the 
pleurisy model by Hyp as compared to indomethacin. Future stud-
ies will address the dissection of the different enzymatic pathways 
leading to PGE
2
 biosynthesis in cellular assays and focus on the 
respective interference with Hyp.
The anti-inflammatory efficiency of Hyp in vivo was confirmed 
in carrageenan-induced rat pleurisy and further demonstrated 
for carrageenan-induced mouse paw edema. During paw edema 
formation, PGE
2
 levels were significantly elevated (Harada et al., 
1982; Guay et al., 2004), and COX inhibitors were shown to pre-
vent the inflammatory response (Gemmell et al., 1979). Also in the 
pleurisy model, PGE
2
 essentially contributes to the inflammatory 
(Dell’Aica et al., 2007), as well as suppression of Ca2+ mobilization, 
leukocyte elastase release, and formation of reactive oxygen species 
in neutrophils (Feisst and Werz, 2004). In addition, we recently 
identified Hyp to inhibit 5-LO and COX-1 in pro-inflammatory 
eicosanoid biosynthesis in vitro (Albert et al., 2002) thereby exhibit-
ing a unique molecular interference of 5-LO at its C2-like domain 
(Feisst et al., 2009). Nevertheless, most of these postulated anti-
inflammatory mechanisms have been essentially identified and 
FigurE 5 | Effects of hyperforin on apoptosis and the expression of 
COX-2 and mPgES-1. A549 cells, 60% confluent, were incubated with  
2 ng ml−1 interleukin-1β together with vehicle (DMSO) or Hyp in cell culture 
medium containing 2% (v v−1) fetal calf serum. Cells were harvested after 
24 h, total cell lysates were prepared and analyzed for the induction of COX-2 
(72 kDa), mPGES-1 (16 kDa) and cleaved PARP (89 kDa) using SDS-PAGE and 
Western blotting. β-Actin (45 kDa) was used as loading control. Data are 
representatives of two to three independent experiments.
FigurE 6 | Effects of hyperforin on carrageenan-induced mouse paw 
edema. (A) Animals (n = 10 for each experimental group) were treated i.p. 
with 0.25, 1, and 4 mg kg−1 Hyp, 5 mg kg−1 indomethacin, or vehicle (2% 
DMSO) 30 min before carrageenan subplantar injection. (B) Inhibition of 
edema formation caused by the treatment with the indicated compounds as 
percentage of vehicle control calculated from the relative areas under the 
curves. Data are given as mean ± SE. n = 10, *p < 0.05, **p < 0.01, 
***p < 0.001 vs. vehicle (2% DMSO) control, ANOVA + Tukey HSD 
post hoc tests.
Table 1 | Effect of Hyp on rat carrageenan-induced pleurisy 4 h after i.p. 
injection.
Treatment Exudate inflammatory PgE2 (ng/rat) 
 volume (ml) cells (×106)
Vehicle (DMSO) 0.44 ± 0.04 103.0 ± 15.4 1.81 ± 0.16
Hyperforin (4 mg kg−1) 0.16 ± 0.05*** 51.3 ± 7.2** 0.97 ± 0.15***
Indomethacin (5 mg kg−1) 0.11 ± 0.04*** 35.8 ± 4.2*** 0.19 ± 0.05***
Data are given as mean ± SE, n = 10, **p < 0.01, ***p < 0.001 vs. vehicle (DMSO 
4%), ANOVA + Tukey HSD post hoc tests.
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